Dark

Check out our Level2View

ALPMF
ASTELLAS PHARMA INC
stock OTC

EOD

May 13, 2025

9.70USD+5.560%(+0.51)598

Pre-market

Dec 31, 1969

0.00USD-100.000%(-9.19)0

After-hours

Dec 31, 1969

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Sep 27, 2021

10:35AM EDT Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan Benzinga

Sep 14, 2021

06:48AM EDT Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold Benzinga

Sep 1, 2021

07:23AM EDT See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial Benzinga

Jul 19, 2021

02:32PM EDT Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data Benzinga

Jul 12, 2021

06:48AM EDT Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer Benzinga

May 11, 2021

12:32PM EDT Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows Benzinga

May 3, 2021

02:48PM EDT Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics Benzinga

Apr 27, 2021

03:37PM EDT Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold Benzinga

Apr 7, 2021

05:54AM EDT FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat Benzinga

Mar 11, 2021

08:21AM EST Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer Benzinga

Feb 19, 2021

01:08PM EST Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies Benzinga

Feb 18, 2021

08:56AM EST Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings Benzinga

Share